Daily Archives: April 3, 2017

Recurrence rates in hepatocellular carcinoma (HCC) patients selected for liver transplantation have drastically improved after the Milan criteria were established. However, about 10% of these patients still experience a recurrence within 5 years.1 For … Continue reading →

Thrift AP, Anderson LA, Murray LJ, et al. nonsteroidal anti-inflammatory drug use is not associated with reduced risk of Barrett’s esophagus. Am J Gastroenterol 2016;111:1528-1535. Continue reading →

We read with interest the results of the PREMIERE trial by Salem et al,1 a randomized controlled trial comparing transarterial chemoembolization (TACE) and yttrium-90 (Y90) transarterial radioembolization in patients with hepatocellular carcinoma (HCC… Continue reading →

“If you come to a fork in the road, take it.”—Yogi Berra Continue reading →

Question: A 60-year-old man with a 5-year history of intermittent diarrhea had been experiencing approximately 5 episodes a day when he visited our hospital. The diarrhea was watery, and he had no abdominal pain, but slight edema was noted in his lower… Continue reading →

Alcoholic fatty liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are 2 of the most common and important liver diseases facing physicians in the 21st century. Because they are so histologically similar, there is a common belief that ALD … Continue reading →

The recent analysis by Ladabaum and Mannalithara concluded that multitarget stool DNA test (MT-sDNA) was less cost-effective than other colorectal cancer (CRC) screening strategies.1 We commend the authors for tackling this important topic, but questio… Continue reading →